Home › Articles › Volume 14, Issue 2 › Sodium Benzoate: A D-Amino Acid Oxidase Inhibitor (Z...
Moradabad, India
Original Article
Miscellaneous

Sodium Benzoate: A D-Amino Acid Oxidase Inhibitor (Zubilance®) Added to Anti-psychotics for the treatment of schizophrenia Management: An Open-Label Study


Volume 14, Issue 2, Pages 27-31

Authors

Debanjan Banerjee1, Krishna Kumar Singh2
Affiliation:
1Consultant, Department of Neuropsychiatrist, Apollo Gleneagles Hospital, Kadapara, Kankurgachi, Kolkata, India.
2Professor, Department of Psychiatry, IGIMS, Patna, India.

Corresponding Author

Debanjan Banerjee

Abstract

Background: Schizophrenia is treated mainly by antipsychotic medication, although one still has to deal with cognitive deficits and suboptimal quality of life often persists. This study evaluates the efficacy of Zubilance®, a sodium benzoate formulation and D-amino acid oxidase inhibitor-as an add-on treatment with antipsychotics-to improve symptom severity, cognitive function, and quality of life in schizophrenia patients. Subjects and Methods: This was a randomized controlled trial with a study duration of 6 weeks. The study group received Zubilance® (500 mg sodium benzoate) in combination with antipsychotics, while the control group received antipsychotics only. Outcomes included symptom severity evaluated by PANSS and CGI scale, cognitive functioning assessed by the MoCA, and quality of life evaluated using the WHOQOL scale. Results: The study group demonstrated a significant improvement in symptom severity, indicated by lower PANSS and CGI scores compared to the control group (p < 0.05). Cognitive function, assessed via MoCA, improved notably in the Zubilance® group, suggesting cognitive enhancement with the add-on treatment. WHOQOL results showed improved quality of life in the study group, correlating with reduced symptoms and cognitive benefits. Conclusion: Our study shows that addition of Zubilance® (Sodium benzoate) to standard antipsychotic drugs treatment improves the patient outcome with enhanced symptom control, cognitive function and quality of life.

Keywords

Sodium Benzoate, Schizophrenia, Cognition, Mental Disorder, DAAO inhibitor, NMDA Hypofunction.

History

Received 02 April 2025

Revised 11 May 2025

Accepted 02 June 2025

DOI

10.47009/ajmr.2025.14.2.6

Author Notes

Corresponding Author: Dr. Debanjan Banerjee, Apollo Gleneagles Hospital, Kadapara, Kankurgachi, Kolkata, India. Email:

Open Access

It is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits authors to retain ownership of the copyright for their content, and allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. https://creativecommons.org/licenses/by/4.0/

Copyright

Copyright: © The author(s), 2025.

Cite this Article

Formats

                                                
Actions
Download PDF
Metrics
10
Downloads
8
Views
Journal
Journal Asian Journal of Medical Research
Volume Volume 14
Issue Issue 2
Year 2025

Purchase access plans

Select the plan that best fits your need

Loading plans...

Statistics:

Views: 0
Downloads: 0

Asian Journal of Medical Research (AJMR) is an international, peer-reviewed, quarterly open-access journal publishing advanced research across medical specialties.

Quick Links

For Authors

© 2026 Asian Journal of Medical Research. All Rights Reserved.Designed and Developed By Kryoni